- Anthony J Dixon, professor1
- 1Australasian College of Cutaneous Oncology, Belmont, VIC 3216, Australia
- anthony{at}acco.org.au
Ten years ago we hoped sentinel lymph node biopsy (SNB) “treatment” would prolong life for patients with melanoma. Then the first Multicenter Selective Lymphadenectomy Trial (MSLT-1) failed to show a five year survival advantage.1 Now we talk of the SNB “test” offering some patients a more accurate survival prediction.
We advise …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.